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A B S T R A C T
The published data remain inconsistent on association between apolipoprotein E (APOE) gene variations and
plasma levels of C-reactive protein (CRP), mainly because of low statistical power of previous studies. To
clarify this question, we analyzed data from large population sample of randomly selected individuals from
seven Czech towns (2,886 males and 3,344 females, the HAPIEE [Health, Alcohol, and Psychosocial factors In
Eastern Europe] study). In both males and females, the lowest levels of plasma hsCRP were observed in the
carriers of the APOE 44 and 43 genotypes. The median (interquartile range, IQR) concentration of hsCRP
in carriers of the most common APOE 33 genotype (two-thirds of participants) was 1.13 mg/l (IQR,
0.56–2.33) in men and 1.23 mg/l (IQR, 0.61–2.65) in women, compared with 0.72 mg/l (IQR, 0.61–0.86) in
male and 0.72 mg/l (IQR, 0.61–0.85) in female carriers of APOE 43/44 genotypes; the differences were
statistically signiﬁcant (p  0.001). The association between APOE and CRP was not materially affected by
adjustment for age, sex, history of cardiovascular disease, or cardiovascular risk factors. This study, the largest
to date, provides robust evidence of an association between plasma hsCRP and the APOE genotype, an
association not explained by history of cardiovascular disease nor its risk factors.




















Open access under CC BY license. . Introduction
There is extensive published data on the potential effect of
ow-grade inﬂammation in the vascular endothelium on athero-
clerosis development [1]. C-reactive protein (CRP), the acute
hase serum protein produced by liver, has often been used as an
verallmarker of inﬂammation. Elevated plasma levels of CRP have
een repeatedly found in patients with cardiovascular disease
CVD) andmyocardial infarction, and it has been proposed that CRP
s an independent risk factor of CVD [2,3], although the pathogenic
nd clinical signiﬁcance of CRP remains controversial [4]. In addi-
ion to CVD, plasma levels of CRP have been also found to correlate
ith CVD risk factors, such as body mass index (BMI), lipid param-
ters, smoking, and dietary habits [5]. Similarly to other risk factors
f atherosclerosis development, plasma levels of CRP are partially
enetically determined [6–9].
Apolipoprotein E (APOE, gene ID 348, OMIM acc Number
07741) is a multifunctional protein that plays a key role in the
etabolism of plasma lipids and is found on the surface of the
riglyceride rich lipoproteins. Three common APOE alleles (2, 3,m
* Corresponding author.
E-mail address: m.bobak@ucl.ac.uk (M. Bobak).
198-8859/10  2010 American Society for Histocompatibility and Immunogenetics. Pub
oi:10.1016/j.humimm.2010.01.008nd 4) and many rare mutations have been described; the fre-
uencies of these variants differ between populations [10–13]. In
eneral, individuals carrying the 4 allele [Cys112¡Arg, rs429358]
ave higher total cholesterol levels and persons carrying the 2
llele [Arg158 ¡ Cys, rs7412] have lower cholesterol than those
arrying the most common 33 genotype. The role of the apoli-
oprotein E, regulated by the APOE gene, in the inﬂammatory re-
ponse has also been suggested [14], and there is some evidence to
upport such an effect from studies in both animal models and
umans [14,15]. Although data on individual variants are not en-
irely consistent, a pro-inﬂammatory state seems associated with
POE 4 allele [14]; the same allele is associated with severe sepsis
n surgical patients [16].
A possible, but physiologically unexplained, association has
een suggested between the common APOE polymorphism and
lasma level of CRP. However, the results to date are contradictory.
lthough initial observations suggested that the highest plasma
evels of CRP are inAPOE 3/e3 carriers and the lowest levels inAPOE
4/e4 and APOE 4/e2 carriers [17], subsequent studies were not
ntirely consistent, as shown in Table 1 [18–35]. A large part of the
pparent inconsistencies is due to the very low statistical power of
ost studies (with a fewexceptions), the use of various preselected


























































































J.A. Hubacek et al. / Human Immunology 71 (2010) 304–308 305ubgroups (e.g., patients with dyslipidemias or CVD, diabetics, or
lderly subjects) and unclear methodology. Clariﬁcation of the as-
ociation between APOE genotype and CRP is important for at least
wo reasons. First, the biologic mechanisms responsible for the
ssociation between APOE genotype and CVD remain unclear; ex-
mining whether associations between APOE and potential cardio-
ascular risk factors (such as CRP) mirror the association of APOE
ith CVD is, therefore, helpful in elucidating the causal pathway.
econd, it has long been recognized that apolipoprotein E, andAPOE
enotype, affect a broad range of biologic functions [36], and there
s interest in the effects ofAPOEon inﬂammatory response rate [14].
In this article, we used data from a large population-based study
ith sufﬁcient statistical power, to investigate differences in
lasma CRP levels by APOE genotype, andwhether such differences
an be explained by history of CVD or its risk factors.
. Subjects and methods
.1. Study subjects
We used data from the Czech part of the HAPIEE (Health, Alco-
ol, and Psychosocial factors In Eastern Europe) study. Details of
he study have been described elsewhere [37]. Brieﬂy, random
opulation samples of men and women aged 45–69 years from
even Czech towns (Jihlava, Havirov, Hradec KralovÊ, Karvina, Kro-
eriz, Liberec, and UstÎ nad Labem) were invited to complete a
uestionnaire and to attend an examination in a clinic. A total of
,856 persons completed the questionnaire (response rate: 55%), of
hom 7,260 attended the examination, 6,920 provided blood sam-
le, and DNA sample was available on 6,748 individuals.
.2. Measurements
High-sensitivity (hs) CRP was measured immunoturbidimetri-
ally by theWHO Lipid Reference Centre in Prague, using the Roche
OBAS (Mannheim, Germany), MIRA autoanalyzer and reagents
rom Orion Diagnostica, Espoo, Finland (kit no. 68025). DNA was
solated from frozen whole blood using the standard salting-out
ethod [38]. Genotyping of the APOE gene was performed as de-
able 1
revious population-based studies on APOE genotype and CRP levels
ain author Year Study population Measure
levels
ravitz et al. [33] 2009 Persons aged 90 3 groups
ngelopoulos et al. [32] 2008 Healthy volunteers Geomet
aan et al. [31] 2008 Elderly Latinos Median
ronroos et al. [23] 2008 General young population Geomet
errahmoune et al. [24] 2007 General population Geomet
ark et al. [34] 2007 Healthy controls Arithme
ahri et al. [26] 2006 Low HDL & normo-lipidaemic
subjects
Geomet
ziakas et al. [29] 2006 Patients with angina & acute
coronary syndrome
Non-par
avaglia et al. [30] 2006 General 65 Binary
ange et al. [20] 2006 Diabetics Geomet
ooijaart et al. [22] 2006 Persons aged 85 Geomet
hasman et al. [25] 2006 General population Geomet
ontu et al. [19] 2006 90 Geomet
iriksdotrir et al. [21] 2006 Older general population Geomet
aschos et al. [28] 2005 Dyslipidaemic Median
udson et al. [27] 2004 Dislipidaemic Geomet
arz et al. [18] 2004 Patients with CHD and
healthy controls
Geomet
ustin et al. [35] 2004 Japanese Americans from 68
kindreds
Geomet
anttari et al. [17] 2001 Cases of MI and controls Arithme
ote: Studies were identified in PubMed using the following combinations of search term
nd (“crp” or “c-reactive protein”).cribed previously [39]. The frequencies of the individual geno- wypes are similar to ﬁndings in neighboring populations [11], and
eviation from the Hardy–Weinberg equilibrium was not statisti-
ally signiﬁcant (p-values were 0.13 in men, 0.22 in women, and
.07 in both genders combined). In seven individuals, a rare APOE
utation Arg136Cyswas detected [40], and these individuals were
xcluded from the study. In further 73 individuals, the genotyping
ailed evenwhen repeated three times. A total of 6,492 persons had
alid data, both on CRP level and APOE genotype.
.3. Statistical analyses
We further excluded subjects who had hsCRP  10 mg/l CRP
evels (n  262) from the analysis because of a possible acute
nfection. The present analyses are thus based on 6,230 subjects
2,886males and 3,344 females)with full data onCRP andAPOE and
ith hsCRP concentrations10 mg/l.
Because the distribution of hsCRP levels is highly skewed, to the
xtent that even logarithmically transformed values are highly
symmetrically distributed, we used nonparametric methods.
irst, we show, for each APOE genotype, and within each sex, the
edian and interquartile range (IQR) of hsCRP concentrations. Sec-
nd, crude differences in hsCRP levels by APOE genotype were
ssessed by the Kruskal–Wallis nonparametric test, separately for
en andwomen. Finally, because the differences in hsCRP by APOE
enotypeswere similar inmenandwomen, data fromboth genders
ere pooled, and the relationship between APOE genotype and
uartile of hsCRP was estimated using ordered logistic regression.
his approach,while notmaking assumption about the distribution
f CRP, allows multivariate analysis and therefore adjustment for
ovariates; we controlled for age, sex, history of myocardial infarc-
ion, angina and stroke (each coded as 0/1), current smoking, total
holesterol, BMI (kg/m2), and hypertension (systolic/diastolic
lood pressure 140/85 mm Hg or antihypertensive medication
n the last 2 weeks). The odds ratio derived from ordered logistic
egression can be interpreted as the weighted mean of (i) odds of
RP quartile 1 vs. quartiles 2–4, (ii) odds of quartiles 1–2 vs. quar-
iles 3–4, and (iii) odds of quartiles 1–3 vs. quartile 4, associated
P Number of
persons
Main ﬁndings Differences in CRP
statistically signiﬁcant?
227 No association No
an 117 Lower CRP in 3/ 4 Marginally
1445 Lower CRP in 3/ 4 Yes
an 1221 Lower in 4 in men, not in
females
Yes/No
an 1223 Lower CRP in 4 Yes
an 119 No association No
an 368 CRP lower in 4 Yes
ic 166 CRP lower in 4 Yes
671 CRP lower in 4 No
an 241 CRP lower in 4 Marginally
an 594 CRP lower in 4 Yes
an 2053 CRP lower in 4 Yes
an 291 CRP lower in 4 Yes
an 2251 CRP lower in 4 Yes
50 CRP lower in 4 No
an 600 CRP lower in 4 yes
an 1309 CRP lower in 4 Yes
an 558 CRP similar in 4 and 3/ 3
but lower than in 2
Marginally
an 177 CRP lower in 4 Yes

















































































































J.A. Hubacek et al. / Human Immunology 71 (2010) 304–308306ulﬁlled (the p-value from the approximate likelihood-ratio test of
roportionality of odds across CRPquartile response categorieswas
.133).
. Results
Descriptive characteristics of the subjects included in the anal-
sis are summarized in Table 2. Themedian CRP levelswere slightly
igher inmen than inwomen (p 0.001) and, as expected, CRPwas
ositively correlated with age, BMI, and smoking (not shown in
able). The distribution of the APOE genotypes in individuals ex-
luded because of CRP concentration  10 mg/l did not differ
rom the general population (APOE 22 0.8%, APOE 23 13.7%,
POE 33 65.3%, APOE 43 16.8%, APOE 42 2.7%, and APOE 44
.8%, not shown in table).
Theplasma levels hsCRPby theAPOE genotypes are summarized
n Table 3. Serum levels of hsCRP differed highly signiﬁcantly be-
ween APOE genotypes, both by all six individual genotypes and by
our groups deﬁned by the presence of the APOE alleles, that is,
arriers of the APOE 2 allele, APOE 33 homozygotes, and APOE 4
arriers. The APOE 24 genotype is also reported separately be-
ause of the uncertainty about pooling with other genotypes. The
ifferences were of similar magnitude in males and females. In
ales, APOE 33 homozygotes had the highest median serum
sCRP; similarly, females with APOE 33 genotype also had high
RP (only very slightly lower median than APOE 42 heterozy-
otes); even in such a large study, however, the numbers of indi-
iduals with speciﬁc uncommon genotypes within each sex were
nsufﬁcient to provide statistically reliable estimates of hsCRP levels.
Given the similarity of associations inmen andwomen (and the
nteractions between sex and APOE were not statistically signiﬁ-
ant), we pooled the data from both genders, and we used ordered
ogistic regression to assess the association between APOE geno-
ype and hsCRP after controlling for covariates (Table 4). The asso-
iations remained strong and highly statistically signiﬁcant after
djustment for the age, history of CVD, smoking, BMI, total choles-
erol, andhypertension. In addition to lower hsCRP in the combined
POE 4 group, both APOE 43 and APOE 44 genotypes had
tatistically lower levels of hsCRP than APOE 33 homozygotes in
hese pooled analyses (because of increased statistical power, com-
ared with sex-speciﬁc analyses).
. Discussion
The present study, the largest on this subject to date, found that
he serum hsCRP is independently determined by the common
enetic polymorphisms within the APOE gene. Given the large size
and hence, high statistical power) of this study, these ﬁndings
rovide robust evidence that the APOE 4 allele is associated with
ow levels of plasma hsCRP.
Previous studies on this subject did not yield results that were
ot entirely consistent. In somepopulations, both 2 and 3 carriers
ere reported to have the highest CRP [17,18]. Some studies of
lderly subjects showed either the highest levels of CRP in APOE 2
able 2
asic characteristics of subjects included in the analysis
Men Women
2886 3344
ge, mean (SD), yr 58.2 (7.2) 57.4 (7.2)
otal cholesterol, mean (SD), mmol/l 5.62 (1.04) 5.82 (1.04)
MI, mean (SD), kg/m2 28.2 (3.9) 27.9 (4.9)
ypertension, % 72.5% 57.9%
urrent smoking prevalence, % 25.9% 20.3%
istory of myocardial infarction, % 7.8% 2.4%
istory of angina, % 5.1% 3.3%
istory of stroke, % 3.5% 2.5%
RP, median (IQR), mg/l 1.08 (0.56, 2.19) 1.19 (0.57, 2.61)
aarriers [19,21] or no effect of APOE genotype on plasma CRP at all
22]. A study in younger adult females found the highest hsCRP
evels in carriers of theAPOE 4 allele [23]. In a recent genome-wide
ssociation study, CRP levels had a signiﬁcant genetic component
nd APOEwas among genes detected to have a signiﬁcant effect on
lasma CRP; however, CRP values by the speciﬁc alleles were not
vailable [8].
The discrepancies in previous ﬁndings aremainly due to the low
tatistical power of most previous studies. In addition, many stud-
es analyzed subjects who included patient’s relatives or prese-
ected subgroups, such as dyslipidemic subjects [17,21,27], ethni-
ally nonhomogenous populations [20], the elderly [19,22], or
amilies of patients [24,26]. There were alsomethodological incon-
istencies; for example, many papers do not specify whether ex-
reme hsCRP levels were excluded from the analyses (because of
he concerns about the presence of acute infection) or the grouping
able 3
edian (IQR) concentrations of CRP by APOE genotype and odds ratios (95%
onﬁdence intervals) from ordered logistic regression (with quartiles of CRP as
ependent variable), by sex
POE N % Median (IQR) of CRP
concentrations (mg/l)
Odds ratio (95% CI)
en
All 2886 100 1.08 (0.56, 2.19) —
22 15 0.5 0.82 (0.45, 2.83) 0.76 (0.29–1.97)
32 309 10.7 1.12 (0.57, 2.16) 0.97 (0.78–1.20)
33 1926 66.7 1.13 (0.56, 2.33) 1.0 (reference)
42 56 1.9 1.10 (0.60, 2.01) 0.93 (0.58–1.47)
43 551 19.1 0.91 (0.52, 1.91) 0.77 (0.65–0.92)
44 29 1.0 0.61 (0.35, 1.19) 0.34 (0.17–0.68)
p  0.0004a
33 1926 66.7 1.13 (0.56, 2.33) 1.0 (reference)
22 32 324 11.2 1.12 (0.56, 2.17) 0.96 (0.78–1.18)
43 44 580 20.1 0.90 (0.49, 1.88) 0.75 (0.63–0.88)
42 56 1.9 1.10 (0.60, 2.01) 0.93 (0.58–1.47)
p  0.0004a
omen
All 3344 100 1.19 (0.57, 2.61) —
22 27 0.8 0.81 (0.52, 2.33) 0.66 (0.33–1.33)
32 399 11.9 1.07 (0.62, 2.42) 0.88 (0.73–1.06)
33 2200 65.8 1.25 (0.61, 2.65) 1.0 (reference)
42 66 2.0 1.33 (0.58, 3.46) 1.15 (0.74–1.79)
43 604 18.1 0.98 (0.48, 2.38) 0.70 (0.60–0.81)
44 48 1.4 0.91 (0.49, 2.64) 0.62 (0.36–1.08)
p  0.0052a
33 2200 65.8 1.25 (0.61, 2.65) 1.0 (reference)
22 32 426 12.7 1.07 (0.61, 2.40) 0.86 (0.72–1.03)
43 44 652 19.5 0.97 (0.48, 2.40) 0.70 (0.60–0.83)




rude and adjusted odds ratios (95% conﬁdence intervals) by APOE genotype from
rdered logistic regression, with quartiles of CRP concentrations as dependent
ariable; pooled data from men and women
POE genotype N % Crude OR (95% CI) Adjusted OR (95% CI)a
ll subjects 6230 100 —
2 42 0.7 0.71 (0.40–1.24) 0.58 (0.31–1.08)
2 708 11.4 0.92 (0.80–1.06) 0.92 (0.79–1.07)
3 4126 66.2 1.0 (reference) 1.0 (reference)
2 122 1.9 1.03 (0.75–1.42) 1.05 (0.75–1.48)
3 1155 18.5 0.73 (0.65–0.83) 0.69 (0.61–0.78)
4 77 1.2 0.50 (0.33–0.76) 0.47 (0.30–0.73)
3 4126 66.2 1.0 1.0 (reference)
2 32 750 12.1 0.91 (0.79–1.04) 0.90 (0.78–1.04)
3 44 1232 19.8 0.72 (0.64–0.81) 0.67 (0.60–0.76)
2 122 1.9 1.03 (0.75–1.42) 1.05 (0.75–1.48)adjusted for age, sex, total cholesterol, hypertension, body mass index, smoking,
























































































J.A. Hubacek et al. / Human Immunology 71 (2010) 304–308 307f APOE genotypes differs between papers. Inappropriate statistics
ay have also contributed to the heterogeneous ﬁndings—most
tudies reported geometrical means of hsCRP but, given the ex-
remely skewed distribution of hsCRP, the use of parametric meth-
ds is likely to produce misleading results. Overall, previous data
ostly suggest lowCRP levels in carriers of 4 comparedwith 33,
ut the inconsistencies in reporting allow neither reliable conclu-
ions nor formal meta-analysis without obtaining the raw data.
Our study overcame many of these limitations. First, its size
roughly equivalent to half of all previous published studies com-
ined) provided sufﬁcient statistical power to study not only
roups of genotypes, but speciﬁc genotypes separately. Second,
ontrary to many previous investigations, our study recruited a
andom general (and ethnically homogenous) population sample,
ather than patients selected for a particular condition, such as
andidates for statin treatment, diabetics, or different ethnicities.
hird, our study sample was slightly younger than many previous
tudies (the mean age in many studies was considerably higher
han sixty years); as age is an important predictor of CRP, studies in
ounger subjects are particularly useful. Fourth, we excluded sub-
ects with high CRP levels, and thus limited misclassiﬁcation be-
ause of possible acute infection, and used nonparametricmethods
hat do not make assumptions about distribution of CRP. Finally,
ur subjectswere phenotypicallywell characterized, enabling us to
iscount history of CVD and risk factors for CVD as possible expla-
ations for the relation between APOE genotype and hsCRP.
The biologic basis for the relationship between APOE and hsCRP
s not clear. Given that both plasma apolipoprotein E and CRP come
rom the same source in organism, the liver, the expression of these
roteins could be regulated by similar factors, but no experimental
vidence has been published so far.
The present results, consistent with most previously published
ata, highlight an important contradiction. On the one hand, indi-
iduals with elevated levels of the hsCRP are at increased risk of
ortality and morbidity from multiple disease states, including
yocardial infarction, stroke, diabetes, metabolic syndrome [3],
nd end stage renal disease [14]. By contrast, APOE 4 is associated
ith increased risk of CVD and end stage renal disease [41]. Yet, the
RP levels are lower in carriers of APOE 4, which is the “risky”
enotype for CVD, and high concentrations of hsCRP, proposed to
e a risk factor of CVD, are not associated with the APOE 4 allele as
ould be expected. To complicate the situation further, there is an
nverse association between plasma apolipoprotein E concentra-
ion and CRP levels [42], and plasma apolipoprotein concentrations
eem to be higher in APOE 2 carriers and lower in APOE 4 carriers
43]. This suggests that the effects of APOE and CRP operate by
ifferent and mutually independent mechanisms, or that the APOE
enotype is associated with, but is not a causal determinant of
lasma CRP levels.
It is possible that slightly elevated CRP levels, based on genetic
redisposition, rather than inﬂammatory status, account for the
levated risk of vascular disease. Indeed, a large prospective study
as shown that variants in theCRP gene are associatedwithmarked
ncrease of CRP levels, but these polymorphisms were not associ-
ted with increased risk of vascular disease [44]. This would allow
or the possibility that adverse effects of increases in CRP levels
re limited to inﬂammation induced environmentally, rather
han genetically.
Our study was not designed to investigate the important ques-
ion of the etiological role of CRP in CVD. However, we have clearly
emonstrated that the APOE genotype inﬂuences CRP concentra-
ions. Future studies are needed to clarify the implication of this
ssociation for the risk of common diseases, such as vascular
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